Have a feature idea you'd love to see implemented?
Let us know!
RCKT Rocket Pharmaceuticals Inc
Price (delayed)
$12.79
Market cap
$1.17B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.73
Enterprise value
$1.12B
Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it
Highlights
Rocket Pharmaceuticals's EPS has increased by 14% YoY
The quick ratio has dropped by 55% year-on-year and by 20% since the previous quarter
The equity has declined by 39% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of RCKT
Market
Valuations
Earnings
Shares outstanding
91.16M
Market cap
$1.17B
Enterprise value
$1.12B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$256.2M
EBITDA
-$247.25M
Free cash flow
-$202.32M
Per share
Balance sheet
Liquidity
EPS
-$2.73
Free cash flow per share
-$2.15
Book value per share
$3.62
Revenue per share
$0
TBVPS
$3.5
Total assets
$393.69M
Total liabilities
$63.92M
Debt
$25.64M
Equity
$329.77M
Working capital
$201.77M
Debt to equity
0.08
Current ratio
6.05
Quick ratio
5.94
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54.2%
Return on equity
-62.6%
Return on invested capital
-73.8%
Return on capital employed
-72.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RCKT stock price
How has the Rocket Pharmaceuticals stock price performed over time
Intraday
-1.92%
1 week
-13.7%
1 month
-27.41%
1 year
-41.52%
YTD
-57.32%
QTD
-30.75%
Financial performance
How have Rocket Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$273.79M
Net income
-$258.08M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 3.1% YoY
RCKT's net income is down by 2.1% YoY
Growth
What is Rocket Pharmaceuticals's growth rate over time
Valuation
What is Rocket Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rocket Pharmaceuticals's EPS has increased by 14% YoY
The equity has declined by 39% year-on-year and by 14% since the previous quarter
The stock's price to book (P/B) is 33% less than its last 4 quarters average of 5.3 and 14% less than its 5-year quarterly average of 4.1
Efficiency
How efficient is Rocket Pharmaceuticals business performance
RCKT's ROE is down by 17% YoY and by 15% from the previous quarter
The return on assets has declined by 14% year-on-year and by 13% since the previous quarter
The ROIC has contracted by 6% from the previous quarter
Dividends
What is RCKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RCKT.
Financial health
How did Rocket Pharmaceuticals financials performed over time
The quick ratio has dropped by 55% year-on-year and by 20% since the previous quarter
Rocket Pharmaceuticals's current ratio has shrunk by 55% YoY and by 22% QoQ
The debt is 92% smaller than the equity
Rocket Pharmaceuticals's debt to equity has soared by 60% YoY and by 14% from the previous quarter
The equity has declined by 39% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.